Frozen versus fresh reconstituted botox for laryngeal dystonia

Abstract

Objectives

To compare the efficacy and side effects of frozen versus fresh reconstituted botulinum toxin type A (BTX-A) in the treatment of laryngeal dystonia.

Study Design and Setting

Prospective open-label crossover study; 43 adult patients with adductor spasmodic dysphonia were randomly treated with fresh or refrozen reconstituted BTX-A at a private voice center. Treatment outcomes were assessed by duration of action and self-rated satisfaction (7 point Likert scale). Side effects of breathiness and dysphagia for liquids were assessed as well.

Results

There was no statistically significant difference in the duration of action (mean, 16.2 ± 8.5 vs 16.0 ± 7.6 weeks) and self-rated satisfaction of the treatment (median, 6.0 vs 6.0 points). The side effects were similar for both BTX-A injection types. In addition, there were no instances of infection for refrozen injections.

Conclusions

BTX-A may be safely used after being reconstituted and frozen or refrozen without a significant loss of effectiveness or additional side effects. In our experience, the period of freezing was on 2 occasions for up to 8 weeks.

Significance

Refrozen BTX-A may be a cost-effective use of an expensive drug.

EBM rating: B-2b

Get full access to this article

View all access options for this article.

References

Blitzer

Brin

Stewart

CF.

Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435–41. (Grade C).

Rubin

Wodchis

Spak

Longitudinal effects of Botox injections on Voice-Related Quality of Life (V-RQOL) for patients with adductory spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2004;130:415–20. (Grade C).

Anderson

Jr.

Proper dose, preparation, and storage of botulinum serotype A. Am J Heath Syst Pharm 2004;(22 Suppl):S24–6. (Grade B).

Jabor

Kaushik

Shayani

Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit. Plast Reconstr Surg 2003;111:2419–26. (Grade B).

Sloop

Cole

Escutin

RO.

Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249–53. (Grade B).

Hexel

De Almeida

Rutowitsch

Multicenter, double-blind study of the efficacy of injections with Botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003;29:523–9. (Grade A).

Bastian

RW.

Factors leading to successful evaluation and management of patients with voice disorders. Ear Nose Throat J 1988;67:411–20.

Tisch

SHD

Brake

Law

Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Autralian experience. J Clin Neuroscience 2003;10:434–8. (Grade C).

Sulica

Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 2004;12:543–8. (Grade B).

10.

Gartlan

Hoffman

HT.

Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135. (Grade D).

11.

Garcia

Fulton

JE.

Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg Oncol 1996;22:39–43. (Grade C).

12.

Damrose

Goldman

Groessl

The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J of Voice 2004;18:415–22. (Grade B).